<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two male patients with achondroplastic <z:hpo ids='HP_0003510'>dwarfism</z:hpo> aged 7-5/12 and 14(1/2) years were treated with human growth hormone 5 mg daily </plain></SENT>
<SENT sid="1" pm="."><plain>Both showed nitrogen retention on balance studies, the older second patient to a marked degree </plain></SENT>
<SENT sid="2" pm="."><plain>In the younger patient, height increased from 95.4 to 106.3 cm on hgh 5 mg daily alone for 14 out of 24 months </plain></SENT>
<SENT sid="3" pm="."><plain>The rate of growth approximately doubled during the first two treatment periods as compared with the pre-treatment rate </plain></SENT>
<SENT sid="4" pm="."><plain>In the second older patient hgh was administered 5 mg daily intramuscularly for 21 out of 33 months </plain></SENT>
<SENT sid="5" pm="."><plain>Growth from 129.6 cm to 137.8 cm occurred with the rate increasing following the addition of Na-1-<z:chebi fb="4" ids="30660">thyroxine</z:chebi> to the routine </plain></SENT>
<SENT sid="6" pm="."><plain>This <z:mp ids='MP_0002865'>increased growth rate</z:mp> occurred during the post-puberty deceleration phase </plain></SENT>
<SENT sid="7" pm="."><plain>Bone ages, interpreted from changes in the phalanges and metacarpals, increased from 4(1/2) to 6 years during 16 months in Case 1, and from 13(1/2) to 18 years in 33 months in Case 2 </plain></SENT>
<SENT sid="8" pm="."><plain>Transient adolescent <z:hpo ids='HP_0000771'>gynecomastia</z:hpo> appeared in Case 2 </plain></SENT>
<SENT sid="9" pm="."><plain>No local or general toxic effects were noted </plain></SENT>
<SENT sid="10" pm="."><plain>These results are suggestive, but whether or not the eventual height of an <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplastic dwarf</z:e> can be significantly altered must await further studies </plain></SENT>
</text></document>